Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca
  • Genentech

This publication has 51 references indexed in Scilit: